Get started
Author

Anna Franceschino

Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa
2003 · D Marin, S Marktel, et al. · Leukemia · 70
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'
2007 · Carlo Gambacorti, Lucia Tornaghi, et al. · Nature Medicine · 48
Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib
2008 · A. Franceschino, L. Tornaghi, et al. · Haematologica · 36
PDF
Imatinib concentrations in human milk
2007 · Carlo B. Gambacorti-Passerini, Lucia Tornaghi, et al. · Blood · 31
Benign Mesenchymal Stromal Cells in Human Sarcomas
2010 · Alexei Morozov, Robert J. Downey, et al. · Clinical Cancer Research · 21
PDF
Imatinib dose increase up to 1200 mg daily can induce new durable complete cytogenetic remissions in relapsed Ph+ chronic myeloid leukemia patients
2005 · R G Piazza, V Magistroni, et al. · Leukemia · 14
The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years
2006 · Rocco G. Piazza, Vera Magistroni, et al. · Blood Cells Molecules and Diseases · 9
Erratum: Corrigendum: In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'
2007 · Carlo Gambacorti-Passerini, Lucia Tornaghi, et al. · Nature Medicine · 5
PDF
Imatinib failed to eradicate chronic myeloid leukemia in a patient with minimal residual disease.
2006 · Anna Franceschino, Lucia Tornaghi, et al. · PubMed · 5
In Vitro and In Vivo Activity of SKI-606, a Novel Abl/Src Inhibitor, Against Imatinib Resistant BCR-ABL+ Neoplastic Cells.
2006 · Miriam Puttini, Addolorata M.L. Coluccia, et al. · Blood · 4
Bim Promoter Is Highly Methylated in Malignant Lymphoid Cell Lines, Leading to Downregulation of Bim Expression and Protection from Apoptosis.
2005 · Rocco G. Piazza, Vera Magistroni, et al. · Blood · 2
The Nup98-HoxA9 Leukemogenic Fusion Protein Blocks Xpo1 and Tap-Mediated Nuclear Export
2011 · Yildirim Dogan, Sutapa Sahay, et al. · Blood · 1
Data from Benign Mesenchymal Stromal Cells in Human Sarcomas
2023 · Alexei Morozov, Robert J. Downey, et al.
Data from Benign Mesenchymal Stromal Cells in Human Sarcomas
2023 · Alexei Morozov, Robert J. Downey, et al.
Supplementary Data from Benign Mesenchymal Stromal Cells in Human Sarcomas
2023 · Alexei Morozov, Robert J. Downey, et al.
PDF
Supplementary Data from Benign Mesenchymal Stromal Cells in Human Sarcomas
2023 · Alexei Morozov, Robert J. Downey, et al.
BIM promoter is epigenetically silenced in malignant lymphoid cells, leading to downregulation of BIM expression and protection from apoptosis
2006 · Magistroni, Rocco Piazza, et al. · Haematologica
Response to ‘D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients’ by Leguay et al
2005 · R G Piazza, V Magistroni, et al. · Leukemia
PDF
Significant Reduction in Fasting Blood Glucose in Nondiabetic Ph+ Chronic Myeloid Leukemia Patients Treated With Imatinib Mesylate
2005 · Lucia Tornaghi, Anna Franceschino, et al. · Haematologica
Autoimmune hepatitis presenting as imatinib toxicity: description of a case and of therapeutic alternatives
2005 · Anna Franceschino, Lucia Tornaghi, et al. · BOA (University of Milano-Bicocca)
Reasons to Eliminate Umbilical Cord Blood Units before Cryopreservation
2001 · C. Pafumi, M. Farina, et al. · Hematology
PDF
Works count: 22
Citation count: 246
H-index: 7
I10-index: 6
Year
Topic
Type